Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-78278343 + JNJ-87189401 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-78278343 | JNJ78278343|JNJ 78278343 | CD3 Antibody 99 | JNJ-78278343 is a humanized IgG1 bispecific antibody that targets KLK2 on tumor cells and CD3 on T lymphocytes, which may lead to T-lymphocyte activation and cell killing of tumor cells expressing KLK2 (NCI Drug Dictionary). | |
JNJ-87189401 | JNJ 87189401|JNJ87189401 | PSMA Antibody 20 | Limited information is currently available on JNJ-87189401, a putative bispecific antibody targeting PSMA and CD28 (Oct 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06095089 | Phase I | JNJ-78278343 + JNJ-87189401 | A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer | Recruiting | USA | FRA | 0 |